Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
Clinical trial NCT07208981 · RECRUITING
Trial details
- NCT number
- NCT07208981
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-14
- Primary completion
- 2028-06-01
- Enrollment
- 169
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.